VPVladimir A. Petrov

Vladimir A. Petrov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vladimir A. Petrov has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expert Council Resolution on Pathogenetically Substantiated Approach to Management and Rehabilitation of Children with Acute Intestinal Infections and Functional Gastrointestinal Disorders with the Inclusion of Probiotics and Intestinal Motility Modulators in Treatment Protocols

    by Leyla S. Namazova-Baranova, Aleksander V. Gorelov, Sergey V. Bel’MEr, Olga S. Gundobina, Alexander S. Dukhanin, Elena V. Kaytukova, Vladimir A. Petrov, Liliya R. Selimzyanova, Denis V. Usenko, Kamilla E. Efendieva

    On March 14, 2026, the Council of Experts was held to address the issue of functional gastrointestinal disorders (FGIDs) in children, including those following acute intestinal infections (AIIs). It was noted that AIIs remain a significant medical and social problem in pediatrics, carrying risks of dehydration, toxic shock, organ damage, and the development of long-term post-infectious complications that impair quality of life. The experts confirmed the key role of baseline therapy for AIIs (oral/parenteral rehydration and diet therapy) and discussed the addition of the probiotic strain Lactobacillus rhamnosus GG (LGG) to standard protocols as an evidence-based approach to reducing the duration and severity of diarrhea and restoring gut microbiota, that may decrease the risk of subsequent FGIDs. In cases of already established FGIDs in children with a predominance of pain and spastic syndromes in the absence of organic pathology, the Council recommended thorough diagnostic evaluation and the use of trimebutine, a universal gastrointestinal motility regulator, including its novel pediatric gel formulation (Dinobutin), which provides analgesic, antispasmodic, and motility-normalizing effects and is potentially associated with higher adherence in children. It was noted that the combined use of LGG and trimebutine (for example, Normobact L and Dinobutin) may yield a more sustained clinical effect in children with FGIDs. The meeting concluded with a proposed management algorithm for patients with AIIs and post-infectious FGIDs, which could significantly improve patient outcomes and quality of life.

  • The Dynamics of SARS-CoV-2 Virus Infection, Effectiveness of Vaccination and Revaccination with Sputnik V and Sputnik Light Drugs for Non-Specialized Medical Workers during the COVID-19 Pandemic

    by V. I. Kiseleva, I. A. Zamulaeva, N. M. Lipunov, L. V. Lyubina, G. P. Bezyaeva, L. V. Panarina, I. L. Ershova, T. A. Agababyan, N. K. Silant’EVa, N. V. Severskaya, et al.

    Introduction. Recently, data accumulated during the COVID-19 pandemic are a subject of thorough analysis and numerous publications of domestic and foreign

  • Open Access

    Evaluation of the efficacy and safety of the drug Raphamin in the treatment of influenza in adults and children aged 12–18 years: analysis of the results of randomized clinical trials

    by A.V. Gorelov, A.A. Zaytsev, Ministry Of Defense Of The Russian Federation Main Military Clinical Hospital Named After Academician N.N. Burdenko, A.G. Malyavin, E.V. Esaulenko, I.E. Kravchenko, V.V. Nikiforov, D.V. Usenko, S.L. Babak, K.E. Novak, et al.

    Оценка эффективности и безопасности препарата Рафамин в терапии гриппа у взрослых и детей 12-18 лет: анализ результатов рандомизированных клинических

  • Open Access

    The results of the All-Russian multicenter study of the use of the antitussive drug Codelac® Broncho in patients with productive cough

    by A.V. Gorelov, S.N. Orlova, D.V. Usenko, N.YU. Pshenichcnaya, Moscow Moniki Named After M.F. Vladimirsky, V.A. Petrov, Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University MEPhI, E.P. Tikhonova, A.A. Poromov

    Результаты Всероссийского многоцентрового исследования применения комбинированного препарата Коделак Бронхо у пациентов с продуктивным кашлем


  • Open Access

    The impact of infection on micronutrient status: the role of vitamins and trace elements in defense against infection

    by S.L. Babak, I.G. Bakulin, L.Z. Bolieva, A.V. Gorelov, M.V. Zhuravleva, O.V. Kalyuzhin, V.M. Kodentsova, A.G. Malyavin, V.A. Petrov, Obninsk Institute for Nuclear Power Engineering branch of the MEPhI National Research Nuclear University, et al.

    Влияние инфекции на микронутриентный статус: роль витаминов и микроэлементов в противоинфекционной защите

  • Open Access

    The use of acetylsalicylic acid medications in the management of common cold and influenza in adults: safety implications

    by S.L. Babak, I.G. Bakulin, L.Z. Bolieva, A.V. Gorelov, M.V. Zhuravleva, O.V. Kalyuzhin, V.M. Kodentsova, A.G. Malyavin, V.A. Petrov, D.V. Usenko, et al.

    Место препаратов ацетилсалициловой кислоты в лечении острых респираторных вирусных инфекций и гриппа у взрослых: вопросы безопасности

  • Open Access

    The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial

    by Vladimir V. Nikiforov, Vladimir A. Petrov, Anatoly A. Stremoukhov., Marina G. Avdeeva, Yury G. Shvarts, Irina E. Kravchenko, Irina V. Nikolaeva, Svetlana E. Ushakova, Oksana N. Belousova, Natal'IA A. Eremina, et al.

    Aim. The search for etiopathogenetic agents to prevent the development of severe and extremely severe COVID-19 remains relevant. A placebo-controlled randomized clinical trial was conducted to evaluate the efficacy and safety of the antibody-based biological drug (Raphamin).Materials and methods. 785 outpatients 18–75 y.o. with laboratory confirmed mild COVID-19 were included within 24 hours from the disease onset. 771 patients were randomized to the group Raphamin (n=382) and the Placebo group (n=389). The study drug/placebo was prescribed for 5 days. The rate of progression to a more severe degree of COVID-19 by day 28 as well as the time to sustained clinical recovery and the frequency of hospitalization were evaluated. Safety was assessed taking into account adverse events, vital signs and laboratory parameters.Results. The number of cases of progression to a more severe degree of COVID-19 in participants receiving Raphamin was 59 (15.5%) [52 (14.6%)] versus placebo – 89 (22.9%) [85 (23.7%)], ITT and [PP] analysis data are presented. The odds ratio between groups was OR=0.6157 [OR=0.5494], 95% confidence interval 0.4276–0.8866 [0.3750–0.8048], which meant a reduction in the chance of progression to a more severe degree by 38.4% [45.1%] or 1.48 [1.62] times; p=0.0088 [p=0.0019]. The time to sustained recovery in the Raphamin group was 4.5±2.4 [4.6±2.4] days, versus placebo – 5.8±4.7 [6.0±4.8] days; p=0.0025 [p=0.0036]. No adverse events with a certain relationship were registered.Conclusion. Raphamin reduces the risk of progression to a more severe degree of the COVID-19 and significantly shortens the duration of clinical symptoms.

  • Open Access

    High-risk human papillomavirus: prevalence, association with clinical and morphological characteristics of invasive cervical cancer

    by L. S. Mkrtchian, V. I. Kiseleva, B. V. Boyko, L. I. Krikunova, V. A. Petrov, V. R. Gusarova, S. A. Ivanov, A. D. Kaprin, I. A. Zamulaeva

    Purpose of the study. Analysis of contemporary literature sources dedicated to the study of characteristics of high oncogenic risk human papillomavirus (HPV), associative links of the virus’s molecular-genetic parameters with the clinical and morphological characteristics of invasive cervical cancer (ICC).Materials and methods. A literature search was conducted in electronic databases including the National Center for Biotechnology Information Search database (PubMed/Medline), ResearchGate, Scopus, Web of Science, Cancer Tomorrow, Global cancer observatory, Cochrane Library, eLIBRARY, DisserCat. The search covered the period from 1990 to 2022 and utilized keywords in Russian and their English translations: cervical cancer, high oncogenic risk HPV, HPV status, HPV genotype, multiple infections, DNA integration, viral load. More than 120 full-text sources were studied, in which the analysis of possible correlations between the parameters of human papillomavirus infection and the clinical and morphological characteristics of cervical cancer was carried out. In review included data from 57 publications. Results. According to most authors, more than 88 % of patients with invasive ICC are HPV-infected. The etiological structure is dominated by HPV 16 (70–72 %), 18 (13–15 %), and 45 (5–7 %) types. Non-detection of HPV HR in cervical cancer is associated, including with a false negative result of the study.The literature analysis showed the presence of an association between HPV status and age, morphological form of the tumor, viral load, high oncogenic risk HPV genotype, presence of deep stromal invasion, and metastatic involvement of lymph nodes. With regard to such molecular genetic parameters of HPV HR as viral load and HPV DNA integration, associative relationship with prognostic important clinical indicators of cervical tumor – the stage of the disease, the loco-regional prevalence of the tumor process, the histological type of tumor – remains the subject of discussion.Conclusion. Many publications report a correlative link between HPV status and high oncogenic risk HPV genotype with such an important factor affecting ICC treatment outcomes as the morphological form of the tumor. Ambiguous conclusions on the presence of an association between a number of molecular-genetic parameters of HPV infection with the main prognostic factor – stage of the disease (due to the heterogeneity of samples, the use of different test systems, and the insufficiently complete account of the main parameters of HPV infection, especially data on viral DNA integration), make it advisable to conduct further research on a representative group of patients with homogeneous diagnostic protocols to determine the most complete spectrum of parameters of high oncogenic risk HPV. In addition, the conducted literature analysis showed the promise of searching for predictors of the effectiveness of specialized treatment of patients with ICC among such HPV infection parameters as HPV status, high oncogenic risk HPV genotype, and the significantly associated physical status of viral DNA.


  • Open Access

    World’s First Experience of the Low-Dose Radionuclide Inhalation Therapy in the Treatment of COVID-19-Associated Viral Pneumonia: Phase 1/2 Clinical Trial

    by Peter Shegay, Alexey Leontyev, Denis Baranovskii, German Davydov, Marina Poluektova, Lyudmila Grivtsova, Vasily Petriev, Valeriy Stepanenko, Igor Gulidov, Valeriy Krylov, et al.

    Objective: Previously, low-dose radiation therapy was used for pneumonia treatment. We aimed to investigate the safety and effectiveness of carbon nanoparticles labeled with Technetium isotope (99mTc) in a form of ultradispersed aerosol in combination with standard COVID-19 therapy. The study was a randomized phase 1 and phase 2 clinical trial of low-dose radionuclide inhalation therapy for patients with COVID-19 related pneumonia. Methods: We enrolled 47 patients with confirmed COVID-19 infection and early laboratory signs of cytokine storm and randomized them into the Treatment and Control groups. We analyzed blood parameters reflecting the COVID-19 severity and inflammatory response. Results: Low-dose 99mTc-labeled inhalation showed a minimal accumulation of radionuclide in lungs in healthy volunteers. We observed no significant differences between the groups before treatment in WBC-count, D-dimer, CRP, Ferritin or LDH levels. We found that Ferritin and LDH levels significantly raised after the 7th day follow-up only in the Control group (p < 0.0001 and p = 0.0005, respectively), while mean values of the same indicators did not change in patients in the Treatment group after the radionuclide treatment. D-dimer values also lowered in the radionuclide treated group, however, this effect was not statistically significant. Furthermore, we observed a significant decrease in CD19+ cell counts in patients of the radionuclide-treated group. Conclusion: Inhalation low-dose radionuclide therapy of 99mTc aerosol affects the major prognostic indicators of COVID-19- related pneumonia restraining inflammatory response. Overall, we identified no evidence of major adverse events in the group receiving radionuclide.


  • Open Access

    Therapy of acute respiratory viral infections in adults in outpatient clinical practice: new opportunities for the prevention of bacterial complications (Results of the observational program RAPORT)

    by Sergey V. Yakovlev, Leonid I. Dvoretskiy, Vladimir A. Petrov, Яковлев Сергей Владимирович

    The frequency of routine prescription of systemic antibacterial drugs in outpatient practice is still unreasonably high despite the desire to reduce them. Under the auspices of the Alliance of Clinical Chemotherapists and Microbiologists, the observational program RAPORT was conducted to assess the therapeutic potential (including bacterial complications preventing) of Raphamin in routine clinical practice in adults with acute respiratory viral infection (ARVI). The program included 14,033 patients aged 1897 years with ARVI who received an investigational drug (ID) as monotherapy (93%) or in combination with basic therapy (7%). The frequency of prophylactic prescribing antibacterial drugs was 0.6%. It was shown that fever duration was 2.311.38 days, and the duration of the disease 3.61.52 days. In 99.4% of patients, ID allowed to avoid the development of bacterial complications and prescription of antibacterial drugs. ID showed a stable therapeutic effect in patients who started treatment late, as well as in patients with a moderate course of ARVI, there was no delay in recovery. The results obtained a broad prospect for the use of ID in order to minimize the number of bacterial complications and the frequency of use of antibiotics in ARVI, which may reduce rate of resistance of topical pathogens in the future.